Pamiparib Combined With Surufatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer

StatusRecruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 2 years 9 months later May 31, 2024 → Mar 2027
See other at-risk trials from Bai-Rong Xia

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from May 31, 2024 to Mar 2027 Show 5 more changesShow less
    • Enrollment reopened
    • Study completion pushed from May 1, 2026 to Dec 2028
    • Eligibility criteria expanded, about 29 words
    • Secondary endpoints: details revised at 1 of 4 entries
    • Site details revised
  2. Re-verified, no change to tracked fieldsv5
  3. Enrollment target: 20 to 37v4
  4. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v3
  5. Study description revisedv2
  6. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Bai-Rong Xia
3 trials monitored
See 1 trial at risk
Ovarian Cancer
1,346 trials monitored
See 97 trials at risk
The goal of this type of clinical trial study is to evaluate the safety and efficacy of Pamiparib combined with Surufatinib as a new neoadjuvant therapy in newly diagnosed patients with advanced ovarian cancer.
Trial Details
NCT Number NCT05652283
Lead Sponsor Bai-Rong Xia
Conditions
(from sponsor)		 Ovarian Cancer
Related terms Ovarian Neoplasms
Enrollment 37 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov